| |
|
|
|
Xtalks, online
2022 -11-07
The acquisition of fresh human tissue is often an impediment to significant research advances. As an alternative, Discovery Life Sciences offers cryopreserved human dissociated tumor cells and tissues as a viable specimen source for many downstream applications, including immunophenotyping, bulk and single-cell sequencing and single-cell functionality. Extensive cellular profiling of these samples by flow cytometry revealed indication-specific trends in the composition of the tumor microenvironment. Additionally, these specimens provide the opportunity to screen for novel biomarker expressions including the expression patterns of the programmed cell death protein-1/ programmed cell death ligand-1 (PD1/PDL1) pathway.
These dissociated tumor cells are amenable to the 10X Genomics single cell pipelines, and workflows have been established to optimize sample preparation into these assays. Finally, as viable cell suspensions, dissociated human tissues can be utilized in both short-term and long-term cultures, and the functionality of tumor-infiltrating T cells can be evaluated using IsoPlexis single-cell proteomics pipelines. Collectively, cryopreserved dissociated human tissue allows for multifaceted analysis of the next generation of cancer therapies.
Register to learn about the applications of cryopreserved human dissociated tumor cells (DTCs) for drug and diagnostic development.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Shawn Fahl, PhD, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2022 -11-07
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|